Biomarker Type: Proteomic
-
A panel of mass spectrometry based serum protein tests for predicting Graft-versus-Host Disease (GvHD) and its severity
-
Retrospective Evaluation of the Randomized, Phase 3 MARQUEE Trial of Tivantinib (T) + Erlotinib (E) vs Placebo (P) + Erlotinib (E) Using VeriStrat in Patients With Previously Treated Non-Squamous NSCLC
-
Serum–based test to identify patients with early relapse treated with adjuvant hormonal therapy
-
Serum mass-spectrometry test in first line advanced NSCLC patients treated with standard chemotherapy regimens
-
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
-
Proteomic Signature Predicts Response To A Therapeutic Vaccine In Pancreas Cancer, Analysis Of Gi-4000-02
-
A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules
-
Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC)
-
Extending the Information Content of the MALDI Analysis of Biological Fluids (Deep MALDI)
-
Serum Mass Spectrometry Analysis in Primary Ovarian Cancer (OC) Treated with Surgery and Adjuvant Chemotherapy (CT)